WHITEHAWK THERAPEUTICS, INC. Pre-Tax Income
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Pre-Tax Income of -$16.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-06
- WHITEHAWK THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$16.64M.
- WHITEHAWK THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$22.19M, a 130.40% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-06-30 was -$52.62M.
- WHITEHAWK THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-03-31 was $73.02M.
- WHITEHAWK THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$20.60M.
- WHITEHAWK THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$63.69M.
- WHITEHAWK THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$65.77M.
- WHITEHAWK THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$60.51M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.64M 10-Q · filed 2026-08-06 | -$38.83M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | -$22.19M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$20.60M 10-K · filed 2026-03-12 | |||
| 2025-06-30 | -$52.62M 10-Q · filed 2026-08-06 | $20.40M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $73.02M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$63.69M 10-K · filed 2026-03-12 | |||
| 2023-12-31 | -$16.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$32.57M derived: sum of 2 quarters · filed 2025-03-28 | -$50.54M derived: sum of 3 quarters · filed 2025-03-28 | -$65.77M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$16.30M 10-Q · filed 2023-11-08 | -$34.27M derived: sum of 2 quarters · filed 2023-11-08 | -$49.50M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | -$17.97M 10-Q · filed 2023-08-09 | -$33.19M 10-Q · filed 2023-08-09 | ||
| 2022-12-31 | -$13.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$28.40M derived: sum of 2 quarters · filed 2024-03-13 | -$46.66M derived: sum of 3 quarters · filed 2024-03-13 | -$60.51M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$14.47M 10-Q · filed 2023-11-08 | -$32.73M derived: sum of 2 quarters · filed 2023-11-08 | -$46.59M 10-Q · filed 2023-11-08 | -$62.58M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$18.26M 10-Q · filed 2023-08-09 | -$32.12M 10-Q · filed 2023-08-09 | -$48.11M derived: sum of 3 quarters · filed 2023-08-09 | -$135.19M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$13.86M 10-Q · filed 2022-05-12 | -$29.85M derived: sum of 2 quarters · filed 2023-03-29 | -$116.94M derived: sum of 3 quarters · filed 2023-03-29 | -$118.47M derived: sum of 4 quarters · filed 2023-03-29 |
| 2021-12-31 | -$15.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$103.08M derived: sum of 2 quarters · filed 2023-03-29 | -$104.61M derived: sum of 3 quarters · filed 2023-03-29 | -$110.09M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$87.09M 10-Q · filed 2022-11-09 | -$88.62M derived: sum of 2 quarters · filed 2022-11-09 | -$94.10M 10-Q · filed 2022-11-09 | -$86.08M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$1.53M 10-Q · filed 2022-08-10 | -$7.01M 10-Q · filed 2022-08-10 | $1.01M derived: sum of 3 quarters · filed 2022-08-10 | -$1.88M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$5.48M 10-Q · filed 2022-05-12 | $2.54M derived: sum of 2 quarters · filed 2022-05-12 | -$346.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $8.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $5.13M derived: sum of 2 quarters · filed 2022-03-17 | -$3.48M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$2.89M 10-Q · filed 2021-11-10 | -$11.50M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |